AK137 (Bispecific Antibody Targeting CD73 and LAG-3) in Patients With Advanced Malignant Tumors
Clinical trial NCT06691360 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06691360
- Sponsor
- Akeso
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-12-01
- Primary completion
- 2027-05-01
- Enrollment
- 87
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.